Our fund have invested in Advanced Silicon Group (ASG). The Company develops advanced biosensors for biopharmaceutical companies using silicon Nanowire photoelectric technology. The use of nanowire creates a high surface to volume ratio, which makes the sensors more sensitive to low proteins. Furthermore, the sensor allows rapid testing at a low cost. The same test using the current predominant ELISA method will cost at least 15 times more than using the Nanowire method. Just recently, the company was asked by Advanced Regenerative Manufacturing Institute (ARMI) to participate in developing rapid coronavirus testing. They are also participating in assisting biomanufacturing related to vaccines for coronavirus infections. The ASG is very strong on its IP. It has at least 25 patents in its portfolio. The company website is at https://advancedsilicongroup.com/